SCHEMBL20546289

SCHEMBL20546289

Cc1ccc([S+]([O-])/N=C/c2ccc(-c3ccccc3)o2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 8/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ GFER P55789 1/20 0.50
▸ MAPT P10636 13/20 0.45
▸ ALDH1A1 P00352 10/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ GAA P10253 3/20 0.44
▸ MEN1 O00255 9/20 0.43
▸ KMT2A Q03164 9/20 0.43
▸ LMNA P02545 8/20 0.43
▸ KDM4E B2RXH2 6/20 0.43
▸ NPC1 O15118 4/20 0.43
▸ NPSR1 Q6W5P4 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ HTT P42858 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ MAPK1 P28482 3/20 0.43
▸ POLB P06746 2/20 0.43
▸ ALOX12 P18054 1/20 0.41
▸ TNNI3 P19429 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20546294 1.00 HPGD (0.50) HPGDSMN1; SMN2GFERMAPTALDH1A1
SCHEMBL20546291 1.00 HPGD (0.50) HPGDSMN1; SMN2GFERMAPTALDH1A1
SCHEMBL28368526 1.00 HPGD (0.50) HPGDSMN1; SMN2GFERMAPTALDH1A1
SCHEMBL12766527 0.78 SMN1; SMN2 (0.41) HPGDSMN1; SMN2MAPTALDH1A1L3MBTL1
SCHEMBL29219636 0.73 POLB (0.57) HPGDSMN1; SMN2GFERMAPTALDH1A1
SCHEMBL29219632 0.73 POLB (0.57) HPGDSMN1; SMN2GFERMAPTALDH1A1
SCHEMBL20545997 0.71 MMP12 (0.34) SMN1; SMN2MAPTALDH1A1L3MBTL1GAA
SCHEMBL20545995 0.71 MMP12 (0.34) SMN1; SMN2MAPTALDH1A1L3MBTL1GAA
SCHEMBL20545999 0.71 MMP12 (0.34) SMN1; SMN2MAPTALDH1A1L3MBTL1GAA
SCHEMBL28372408 0.71 MMP12 (0.34) SMN1; SMN2MAPTALDH1A1L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615514-B1 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF AVIARA PHARMACEUTICALS INC (US) 2023-11-22 — — EP disclosed
US-10875875-B2 Propionic acid derivatives and methods of use thereof AVIARA PHARMACEUTICALS, INC. (US) 2020-12-29 — — US disclosed
CN-110914242-A Propionic acid derivatives and methods of use thereof 阿维亚拉药品有限公司 2020-03-24 — — CN disclosed
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof AVIARA PHARMACEUTICALS, INC. (US) 2018-11-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof ITGB3, ITGA1, ITGB5 HPGD 1373/4885SMN1; SMN2 2021/4885GFER 2072/4885
US-10875875-B2 Propionic acid derivatives and methods of use thereof ITGB3, ITGA1, ITGB5 HPGD 1373/4885SMN1; SMN2 2021/4885GFER 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback